Skip to main
ANVS

Annovis Bio (ANVS) Stock Forecast & Price Target

Annovis Bio (ANVS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Annovis Bio is showing promising signs of demand for their clinical trials, with the completion of enrollment in the pivotal Phase 3 trial for their flagship drug candidate, buntanetap. Additionally, the company has a potential NDA submission in the works for the disease progression component of their product. With positive Phase 3 trial results, fast track designation from the FDA, and potential collaboration revenue, Annovis Bio has strong potential for growth in the future.

Bears say

Annovis Bio is facing major risks to their stock, including a potential lack of FDA acceptance and eventual unsuccessful launches or commercial performance. They also have a modest cash runway and are focused on difficult-to-treat diseases, which could lead to trial failures due to lack of efficacy or safety. Additionally, increased competition and pricing pressures could negatively impact their financial performance in the future.

Annovis Bio (ANVS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annovis Bio (ANVS) Forecast

Analysts have given Annovis Bio (ANVS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Annovis Bio (ANVS) has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annovis Bio (ANVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.